The trial did not meet its primary endpoint of mean change in best corrected visual acuity (BCVA ... 3 clinical program, and for their contributions in investigating new treatments for wet AMD.” ...

The sponsor of two phase 3 clinical trials of an add-on agent to treat ... endpoint of improvement in best corrected visual acuity (BCVA) after a year of treatment when compared with the singular ...

ShORe Phase 3 topline results accelerated; trial did not meet primary endpoint of mean change in BCVA from ... degeneration (wet AMD), today announced updates on its Phase 3 clinical program ...

The trial did not meet its primary endpoint of mean change in best corrected visual acuity (BCVA ... grateful to all patients, clinical investigators and their staff around the world who participated ...

Suprachoroidal injection of this proprietary suspension of axitinib has demonstrated meaningful potential in Phase 1/2a and Phase 2b wet AMD clinical trials in which CLS-AX was well tolerated and ...

announced today its decision to discontinue its clinical trials for Wet Age-Related Macular Degeneration (Wet AMD (NASDAQ:AMD)). This decision was disclosed in a report filed with the U.S ...

After announcing that lead candidate sozinibercept (OPT-302) failed the phase III Coast trial in wet age-related macular degeneration (AMD), Opthea has now decided to close the Coast trial as well as ...

Opthea Ltd (NASDAQ:OPT), an Australian biotechnology company specializing in biological products with a market capitalization of $464 million, announced today its decision to discontinue its clinical ...